CEO Tom Polen highlighted that Q2 revenues grew 6% in total or 0.9% organically, below expectations. The underperformance was mainly attributed to reduced global research funding affecting Biosciences ...
Corporate insiders have not been impressively active so far in 2025. Despite a great deal of volatility, insiders have been held back by a rising wave of uncertainty. With the tariffs confusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results